Scarica l'app Stockscreener
49.73
1.76%
-0.825
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché AKRO Giù?
Forum
Previsione
Precedente Chiudi:
$50.56
Aprire:
$50.67
Volume 24 ore:
448.98K
Relative Volume:
0.29
Capitalizzazione di mercato:
$3.96B
Reddito:
-
Utile/perdita netta:
$-269.44M
Rapporto P/E:
-13.26
EPS:
-3.75
Flusso di cassa netto:
$-262.63M
1 W Prestazione:
-3.33%
1M Prestazione:
-11.60%
6M Prestazione:
-3.50%
1 anno Prestazione:
+76.64%
Intervallo 1D:
$49.21
$50.69
Intervallo di 1 settimana:
$49.21
$52.32
Portata 52W:
$21.34
$58.40
Akero Therapeutics Inc Stock (AKRO) Company Profile
Nome
Akero Therapeutics Inc
Settore
Industria
Telefono
650-487-6488
Indirizzo
601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO, CA
Confronta AKRO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AKRO
Akero Therapeutics Inc
|
49.72 | 4.03B | 0 | -269.44M | -262.63M | -3.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.15 | 120.60B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.15 | 60.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.85 | 42.87B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
594.64 | 36.23B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.87 | 31.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Akero Therapeutics Inc Stock (AKRO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-30 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-01-27 | Reiterato | H.C. Wainwright | Buy |
| 2024-11-18 | Iniziato | Citigroup | Buy |
| 2024-04-22 | Ripresa | BofA Securities | Neutral |
| 2023-09-19 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-08-28 | Iniziato | UBS | Buy |
| 2023-01-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-09-14 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2021-10-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-10 | Iniziato | BofA Securities | Buy |
| 2021-02-26 | Iniziato | Guggenheim | Buy |
| 2020-09-10 | Iniziato | Morgan Stanley | Overweight |
| 2020-07-20 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-07 | Iniziato | Chardan Capital Markets | Buy |
| 2020-07-01 | Reiterato | H.C. Wainwright | Buy |
| 2020-03-02 | Iniziato | H.C. Wainwright | Buy |
| 2020-02-10 | Iniziato | Canaccord Genuity | Buy |
| 2019-07-15 | Iniziato | Evercore ISI | Outperform |
| 2019-07-15 | Iniziato | JP Morgan | Overweight |
| 2019-07-15 | Iniziato | Jefferies | Buy |
| 2019-07-15 | Iniziato | ROTH Capital | Buy |
Mostra tutto
Akero Therapeutics Inc Borsa (AKRO) Ultime notizie
Teachers Retirement System of The State of Kentucky Decreases Holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
How strong is Akero Therapeutics Inc. company’s balance sheetFree Daily Trading Room Entry - jammulinksnews.com
What makes Akero Therapeutics Inc. stock price move sharplyMarket Forecast Picks That Work - jammulinksnews.com
Is Akero Therapeutics Inc. a growth stock or a value stockUnlock expert trading strategies for growth - jammulinksnews.com
Jennison Associates LLC Invests $533,000 in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Readystate Asset Management LP Acquires Shares of 100,500 Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock Holdings Lowered by Kennondale Capital Management LLC - MarketBeat
What analysts say about Akero Therapeutics Inc. stockTremendous growth potential - PrintWeekIndia
Is Akero Therapeutics Inc. a good long term investmentFast-track wealth growth - PrintWeekIndia
What drives Akero Therapeutics Inc. stock priceHigh-margin investment plays - PrintWeekIndia
Akero Therapeutics, Inc. (NASDAQ:AKRO) Shares Purchased by Bank of New York Mellon Corp - MarketBeat
AstraZeneca’s Anselamimab Misses Primary Endpoint in Amyloidosis Trials, Shows Promise in Subgroup - Insider Monkey
Is Akero Therapeutics Inc. stock a growth or value playFree Trend-Following Techniques - jammulinksnews.com
How to Take Advantage of moves in (AKRO) - news.stocktradersdaily.com
Edgestream Partners L.P. Acquires Shares of 6,947 Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Akero Therapeutics Inc. Stock Analysis and ForecastFastest-growing stock picks - Autocar Professional
5,565 Shares in Akero Therapeutics, Inc. (NASDAQ:AKRO) Bought by Xponance Inc. - MarketBeat
Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells $529,500.00 in Stock - MarketBeat
257,025 Shares in Akero Therapeutics, Inc. (NASDAQ:AKRO) Purchased by Principal Financial Group Inc. - MarketBeat
Mirum Gains 35% in 3 Months: How Should You Play the Stock? - The Globe and Mail
Akero Therapeutics, Inc. (NASDAQ:AKRO) Receives $82.50 Average Price Target from Analysts - MarketBeat
Akero Therapeutics Inc Azioni (AKRO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Akero Therapeutics Inc Azioni (AKRO) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Yale Catriona | Chief Development Officer |
Jul 16 '25 |
Sale |
52.95 |
10,000 |
529,467 |
91,488 |
| Cheng Andrew | President and CEO |
Jul 10 '25 |
Sale |
51.16 |
30,000 |
1,534,895 |
520,757 |
| Rolph Timothy | Chief Scientific Officer |
Jul 07 '25 |
Option Exercise |
21.09 |
12,500 |
263,625 |
179,624 |
| Rolph Timothy | Chief Scientific Officer |
Jul 07 '25 |
Sale |
51.09 |
12,500 |
638,661 |
167,124 |
1.09%
1.02%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):